pubmed-article:12381771 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12381771 | lifeskim:mentions | umls-concept:C0242694 | lld:lifeskim |
pubmed-article:12381771 | lifeskim:mentions | umls-concept:C1882687 | lld:lifeskim |
pubmed-article:12381771 | lifeskim:mentions | umls-concept:C0008932 | lld:lifeskim |
pubmed-article:12381771 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:12381771 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:12381771 | pubmed:dateCreated | 2002-10-16 | lld:pubmed |
pubmed-article:12381771 | pubmed:abstractText | Myocyte-specific necrosis in the heart and soleus muscle of adult male Wistar rats was investigated in response to a single subcutaneous injection of the anabolic beta(2)-adrenergic receptor agonist clenbuterol. Necrosis was immunohistochemically detected by administration of a myosin antibody 1 h before the clenbuterol challenge and quantified by using image analysis. Clenbuterol-induced myocyte necrosis occurred against a background of zero damage in control muscles. In the heart, the clenbuterol-induced necrosis was not uniform, being more abundant in the left subendocardium and peaking 2.4 mm from the apex. After position (2.4 mm from the apex), dose (5 mg clenbuterol/kg), and sampling time (12 h) were optimized, maximum cardiomyocyte necrosis was found to be 1.0 +/- 0.2%. In response to the same parameters (i.e., 5 mg of clenbuterol and sampled at 12 h), skeletal myocyte necrosis was 4.4 +/- 0.8% in the soleus. These data show significant myocyte-specific necrosis in the heart and skeletal muscle of the rat. Such irreversible damage in the heart suggests that clenbuterol may be damaging to long-term health. | lld:pubmed |
pubmed-article:12381771 | pubmed:language | eng | lld:pubmed |
pubmed-article:12381771 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12381771 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12381771 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12381771 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12381771 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12381771 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12381771 | pubmed:month | Nov | lld:pubmed |
pubmed-article:12381771 | pubmed:issn | 8750-7587 | lld:pubmed |
pubmed-article:12381771 | pubmed:author | pubmed-author:GoldspinkDavi... | lld:pubmed |
pubmed-article:12381771 | pubmed:author | pubmed-author:BurnistonJati... | lld:pubmed |
pubmed-article:12381771 | pubmed:author | pubmed-author:NgYeelanY | lld:pubmed |
pubmed-article:12381771 | pubmed:author | pubmed-author:ClarkWilliam... | lld:pubmed |
pubmed-article:12381771 | pubmed:author | pubmed-author:ColyerJohnJ | lld:pubmed |
pubmed-article:12381771 | pubmed:author | pubmed-author:TanLip-BunLB | lld:pubmed |
pubmed-article:12381771 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12381771 | pubmed:volume | 93 | lld:pubmed |
pubmed-article:12381771 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12381771 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12381771 | pubmed:pagination | 1824-32 | lld:pubmed |
pubmed-article:12381771 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:meshHeading | pubmed-meshheading:12381771... | lld:pubmed |
pubmed-article:12381771 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:12381771 | pubmed:articleTitle | Myotoxic effects of clenbuterol in the rat heart and soleus muscle. | lld:pubmed |
pubmed-article:12381771 | pubmed:affiliation | Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool L3 2ET, United Kingdom. hhsjburn@livjm.ac.jp | lld:pubmed |
pubmed-article:12381771 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12381771 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12381771 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12381771 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12381771 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12381771 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12381771 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12381771 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12381771 | lld:pubmed |